Development of forced degradation and stability indicating studies of drugs—A review  by Blessy, M et al.
Contents lists available at ScienceDirect
www.elsevier.com/locate/jpa
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis 2014;4(3):159–1652095-1779 & 2013 Xi
http://dx.doi.org/10.10
nCorresponding auth
E-mail address: bl
Peer review under rwww.sciencedirect.comREVIEW PAPERDevelopment of forced degradation and stability
indicating studies of drugs—A reviewBlessy Mn, Ruchi D. Patel, Prajesh N. Prajapati, Y.K. AgrawalDepartment of Pharmaceutical Analysis, Institute of Research and Development, Gujarat Forensic Sciences University,
Sector-18A, Nr. Police Bhavan, Gandhinagar 382007, Gujarat, India
Received 24 January 2013; accepted 10 September 2013
Available online 17 September 2013KEYWORDS
Degradation conditions;
Degradation product;
Forced degradation;
Stability indicating
method;
Stress testing’an Jiaotong Univer
16/j.jpha.2013.09.00
or. Tel.: þ91 97230
essy_51289@yahoo
esponsibility of Xi’Abstract Forced degradation is a degradation of new drug substance and drug product at conditions
more severe than accelerated conditions. It is required to demonstrate speciﬁcity of stability indicating
methods and also provides an insight into degradation pathways and degradation products of the drug
substance and helps in elucidation of the structure of the degradation products. Forced degradation studies
show the chemical behavior of the molecule which in turn helps in the development of formulation and
package. In addition, the regulatory guidance is very general and does not explain about the performance
of forced degradation studies. Thus, this review discusses the current trends in performance of forced
degradation studies by providing a strategy for conducting studies on degradation mechanisms and also
describes the analytical methods helpful for development of stability indicating method.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Chemical stability of pharmaceutical molecules is a matter of great
concern as it affects the safety and efﬁcacy of the drug product. The
FDA and ICH guidances state the requirement of stability testing data
to understand how the quality of a drug substance and drug productsity. Production and hosting by Elsev
3
01703; fax: þ91 079 23247465.
.co.in (Blessy M).
an Jiaotong University.changes with time under the inﬂuence of various environmental factors.
Knowledge of the stability of molecule helps in selecting proper
formulation and package as well as providing proper storage conditions
and shelf life, which is essential for regulatory documentation. Forced
degradation is a process that involves degradation of drug products and
drug substances at conditions more severe than accelerated conditions
and thus generates degradation products that can be studied to
determine the stability of the molecule. The ICH guideline states that
stress testing is intended to identify the likely degradation products
which further helps in determination of the intrinsic stability of the
molecule and establishing degradation pathways, and to validate the
stability indicating procedures used [1]. But these guidelines are very
general in conduct of forced degradation and do not provide details
about the practical approach towards stress testing. Although forcedier B.V. All rights reserved.
Blessy M et al.160degradation studies are a regulatory requirement and scientiﬁc necessity
during drug development, it is not considered as a requirement for
formal stability program.
It has become mandatory to perform stability studies of new
drug moiety before ﬁling in registration dossier. The stability
studies include long term studies (12 months) and accelerated
stability studies (6 months). But intermediate studies (6 months)
can be performed at conditions milder than that used in
accelerated studies. So the study of degradation products like
separation, identiﬁcation and quantitation would take even more
time. As compared to stability studies, forced degradation studies
help in generating degradants in much shorter span of time,
mostly a few weeks. The samples generated from forced
degradation can be used to develop the stability indicating
method which can be applied latter for the analysis of samples
generated from accelerated and long term stability studies. This
review provides a proposal on the practical performance of
forced degradation and its application for the development of
stability indicating method.2. Objective of forced degradation studies
Forced degradation studies are carried out to achieve the following
purposes:1. To establish degradation pathways of drug substances and
drug products.2. To differentiate degradation products that are related to drug
products from those that are generated from non-drug product
in a formulation.3. To elucidate the structure of degradation products.
4. To determine the intrinsic stability of a drug substance in
formulation.
5. To reveal the degradation mechanisms such as hydrolysis,
oxidation, thermolysis or photolysis of the drug substance
and drug product [1,2].6. To establish stability indicating nature of a developed method.
7. To understand the chemical properties of drug molecules.
8. To generate more stable formulations.
9. To produce a degradation proﬁle similar to that of what
would be observed in a formal stability study under ICH
conditions.10. To solve stability-related problems [3].3. Time to perform forced degradation
It is very important to know when to perform forced degradation
studies for the development of new drug substance and new drug
product. FDA guidance states that stress testing should be performed
in phase III of regulatory submission process. Stress studies should be
done in different pH solutions, in the presence of oxygen and light,
and at elevated temperatures and humidity levels to determine the
stability of the drug substance. These stress studies are conducted on
a single batch. The results should be summarized and submitted in an
annual report [4]. However, starting stress testing early in preclinical
phase or phase I of clinical trials is highly encouraged and should be
conducted on drug substance to obtain sufﬁcient time for identifying
degradation products and structure elucidation as well as optimizing
the stress conditions. An early stress study also gives timely
recommendations for making improvements in the manufacturingprocess and proper selection of stability-indicating analytical proce-
dures [5,6].4. Limits for degradation
The question of how much degradation is sufﬁcient has been the
topic of many discussions amongst pharmaceutical scientists. Degra-
dation of drug substances between 5% and 20% has been accepted as
reasonable for validation of chromatographic assays [7,8]. Some
pharmaceutical scientists think 10% degradation is optimal for use in
analytical validation for small pharmaceutical molecules for which
acceptable stability limits of 90% of label claim is common [9].
Others suggested that drug substance spiked with a mixture of known
degradation products can be used to challenge the methods employed
for monitoring stability of drug product [2]. No such limits for
physiochemical changes, loss of activity or degradation during shelf
life have been established for individual types or groups of biological
products [10].
It is not necessary that forced degradation would result in a
degradation product. The study can be terminated if no degradation
is seen after drug substance or drug product has been exposed to
stress conditions than those conditions mentioned in an accelerated
stability protocol [11]. This is indicative of the stability of the
molecule under test. Over-stressing a sample may lead to the
formation of a secondary degradation product that would not be
seen in formal shelf-life stability studies and under-stressing may
not generate sufﬁcient degradation products [12]. Protocols for
generation of product-related degradation may differ for drug
substance and drug product due to differences in matrices and
concentrations. It is recommended that maximum of 14 days for
stress testing in solution (a maximum of 24 h for oxidative tests) to
provide stressed samples for methods development [13].5. Strategy for selection of degradation conditions
Forced degradation is carried out to produce representative samples
for developing stability-indicating methods for drug substances and
drug products. The choice of stress conditions should be consistent
with the product's decomposition under normal manufacturing,
storage, and use conditions which are speciﬁc in each case [9].
A general protocol of degradation conditions used for drug substance
and drug product is shown in Scheme 1.
A minimal list of stress factors suggested for forced degradation
studies must include acid and base hydrolysis, thermal degradation,
photolysis, oxidation [5,14–16] and may include freeze–thaw cycles
and shear [10]. There is no speciﬁcation in regulatory guidelines
about the conditions of pH, temperature and speciﬁc oxidizing agents
to be used. The design of photolysis studies is left to the applicant's
discretion although Q1B speciﬁes that the light source should produce
combined visible and ultraviolet (UV, 320–400 nm) outputs, and that
exposure levels should be justiﬁed [11]. The initial trial should have
the aim to come upon the conditions that degrade the drug by
approximately 10%. Some conditions mostly used for forced
degradation studies are presented in Table 1 [17].
Some scientists have found it practical to begin with extreme
conditions such as 80 1C or even higher temperatures and testing at
shorter (2, 5, 8, 24 h, etc.) multiple time points, so that the rate of
degradation can be evaluated [18]. The primary degradants and their
secondary degradations products can be distinguished by testing at
early time points and thus help in a better degradation pathway
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Scheme 1 An illustrative ﬂowchart describing various stress conditions used for degradation of drug substance and drug product.
Table 1 Conditions mostly used for forced degradation studies.
Degradation type Experimental conditions Storage conditions Sampling time (days)
Hydrolysis Control API (no acid or base) 40 1C, 60 1C 1,3,5
0.1 M HCl 40 1C, 60 1C 1,3,5
0.1 M NaOH 40 1C, 60 1C 1,3,5
Acid control (no API) 40 1C, 60 1C 1,3,5
Base control (no API) 40 1C, 60 1C 1,3,5
pH: 2,4,6,8 40 1C, 60 1C 1,3,5
Oxidation 3% H2O2 25 1C, 60 1C 1,3,5
Peroxide control 25 1C, 60 1C 1,3,5
Azobisisobutyronitrile (AIBN) 40 1C, 60 1C 1,3,5
AIBN control 40 1C, 60 1C 1,3,5
Photolytic Light 1 ICH NA 1,3,5
Light 3 ICH NA 1,3,5
Light control NA 1,3,5
Thermal Heat chamber 60 1C 1,3,5
Heat chamber 60 1C/75% RH 1,3,5
Heat chamber 80 1C 1,3,5
Heat chamber 80 1C/75% RH 1,3,5
Heat control Room temp. 1,3,5
Ref.: [17].
NA: Not applicable.
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sidering the drug substance to be labile and doing degradation at the
conditions mentioned in Table 1. Then stress would be increased or
decreased to obtain sufﬁcient degradation. As compared to harsher
conditions and less time approach, this strategy is better due to the
following reasons: (i) there may be a change in mechanism of
reaction when a harsh condition is used, and (ii) there is a practical
problem in neutralizing or diluting every sample, when it contains a
high concentration of reactants, e.g., acid or base, before an injection
can be made on the HPLC column. Both these reasons are strong
enough to suggest that as normal as possible conditions should be
used for causing the decomposition of the drug [19]. Studies shouldbe repeated when formulations or methods change because the
change may lead to the production of new degradation products.6. Selection of drug concentration
Which concentration of drug should be used for degradation study
has not been speciﬁed in regulatory guidance. It is recommended that
the studies should be initiated at a concentration of 1 mg/mL [20].
By using drug concentration of 1 mg/mL, it is usually possible to get
even minor decomposition products in the range of detection. It is
suggested that some degradation studies should also be done at
Blessy M et al.162a concentration which the drug is expected to be present in the ﬁnal
formulations [19]. The reason for proposing this is the examples of
aminopenicillins and aminocephalosporins where a range of poly-
meric products have been found to be formed in commercial
preparations containing drug in high concentrations [21].7. Degradation conditions
7.1. Hydrolytic conditions
Hydrolysis is one of the most common degradation chemical
reactions over a wide range of pH. Hydrolysis is a chemical process
that includes decomposition of a chemical compound by reaction
with water. Hydrolytic study under acidic and basic condition
involves catalysis of ionizable functional groups present in the
molecule. Acid or base stress testing involves forced degradation of
a drug substance by exposure to acidic or basic conditions which
generates primary degradants in desirable range. The selection of the
type and concentrations of acid or base depends on the stability of the
drug substance. Hydrochloric acid or sulfuric acids (0.1–1 M) for acid
hydrolysis and sodium hydroxide or potassium hydroxide (0.1–1 M)
for base hydrolysis are suggested as suitable reagents for hydrolysis
[20,22]. If the compounds for stress testing are poorly soluble in
water, then co-solvents can be used to dissolve them in HCl or
NaOH. The selection of co-solvent is based on the drug substance
structure. Stress testing trial is normally started at room temperature
and if there is no degradation, elevated temperature (50–70 1C) is
applied. Stress testing should not exceed more than 7 days. The
degraded sample is then neutralized using suitable acid, base or
buffer, to avoid further decomposition.
7.2. Oxidation conditions
Hydrogen peroxide is widely used for oxidation of drug substances
in forced degradation studies but other oxidizing agents such as
metal ions, oxygen, and radical initiators (e.g., azobisisobutyroni-
trile, AIBN) can also be used. Selection of an oxidizing agent, its
concentration, and conditions depends on the drug substance. It is
reported that subjecting the solutions to 0.1–3% hydrogen per-
oxide at neutral pH and room temperature for seven days or up to a
maximum 20% degradation could potentially generate relevant
degradation products [22]. The oxidative degradation of drug
substance involves an electron transfer mechanism to form reactive
anions and cations. Amines, sulﬁdes and phenols are susceptible to
electron transfer oxidation to give N-oxides, hydroxylamine,
sulfones and sulfoxide [23]. The functional group with labile
hydrogen like benzylic carbon, allylic carbon, and tertiary carbon
or α-positions with respect to hetro atom is susceptible to
oxidation to form hydro peroxides, hydroxide or ketone [24,25].
7.3. Photolytic conditions
The photo stability testing of drug substances must be evaluated to
demonstrate that a light exposure does not result in unacceptable
change. Photo stability studies are performed to generate primary
degradants of drug substance by exposure to UV or ﬂuorescent
conditions. Some recommended conditions for photostability
testing are described in ICH guidelines [11]. Samples of drug
substance and solid/liquid drug product should be exposed to a
minimum of 1.2 million lx h and 200 W h/m2 light. The mostcommonly accepted wavelength of light is in the range of 300–
800 nm to cause the photolytic degradation [26,27]. The maximum
illumination recommended is 6 million lx h [25]. Light stress
conditions can induce photo oxidation by free radical mechanism.
Functional groups like carbonyls, nitro aromatic, N-oxide, alkenes,
aryl chlorides, weak C–H and O–H bonds, sulﬁdes and polyenes are
likely to introduce drug photosensitivity [28].
7.4. Thermal conditions
Thermal degradation (e.g., dry heat and wet heat) should be carried
out at more strenuous conditions than recommended ICH Q1A
accelerated testing conditions. Samples of solid-state drug sub-
stances and drug products should be exposed to dry and wet heat,
while liquid drug products should be exposed to dry heat. Studies
may be conducted at higher temperatures for a shorter period [22].
Effect of temperature on thermal degradation of a substance is
studied through the Arrhenius equation:
k¼ AeEa=RT
where k is speciﬁc reaction rate, A is frequency factor, Ea is energy
of activation, R is gas constant (1.987 cal/deg mole) and T is
absolute temperature [25,29,30]. Thermal degradation study is
carried out at 40–80 1C.8. Stability indicating method
A stability indicating method (SIM) is an analytical procedure used
to quantitate the decrease in the amount of the active pharmaceutical
ingredient (API) in drug product due to degradation. According to
an FDA guidance document, a stability-indicating method is a
validated quantitative analytical procedure that can be used to detect
how the stability of the drug substances and drug products changes
with time. A stability-indicating method accurately measures the
changes in active ingredients concentration without interference
from other degradation products, impurities and excipients [14].
Stress testing is carried out to demonstrate speciﬁcity of the
developed method to measure the changes in concentration of drug
substance when little information is available about potential
degradation product. The development of a suitable stability
indicating method provides a background for the pre-formulation
studies, stability studies and the development of proper storage
requirements. Bakshi and Singh [19] discussed some critical issues
about developing stability indicating methods. Dolan [31] made
comments and suggestions on stability indicating assays. Smela [32]
discussed from a regulatory point of view about stability indicating
analytical methods. The RP-HPLC is a most widely used analytical
tool for separation and quantifying the impurities and it is most
frequently coupled with a UV detector [29]. The following are the
steps involved for development of SIM on HPLC which meets the
regulatory requirements.
8.1. Sample generation
For generating samples for SIM the API is force degraded at
conditions more severe than accelerated degradation conditions.
It involves degradation of drug at hydrolytic, oxidative, photolytic
and thermal conditions as discussed earlier. The forced degrada-
tion of API in solid state and solution form is carried out with an
aim to generate degradation products which are likely to be formed
Development of forced degradation and stability indicating studies of drugs—A review 163in realistic storage conditions [33]. This sample is then used to
develop an SIM.
8.2. Method development and optimization
Before starting the method development, various physiochemical
properties like pKa value, log P, solubility and absorption max-
imum of the drug must be known, for it lays a foundation for
HPLC method development. Log P and solubility helps select
mobile phase and sample solvent while pKa value helps determine
the pH of the mobile phase [19].
Reverse phase column is a preferred choice to start the separation of
sample components as the degradation is carried out in aqueous
solution. Methanol, water and acetonitrile can be used as mobile phase
in various ratios for the initial stages of separation. Selection between
methanol and acetonitrile for organic phase is based on the solubility of
the analyte. Initially the water: organic phase ratio can be kept at 50:50
and suitable modiﬁcations can be made as trials proceed to obtain a
good separation of peaks. Latter buffer can be added if it is required to
obtain better peak separation and peak symmetry. If the method is to be
extended to liquid chromatography–mass spectrometry (LC–MS), then
mobile phase buffer should be MS compatible like triﬂouroacetic acid
and ammonium formate. Variation in column temperature affects the
selectivity of the method as analytes respond differently to temperature
changes. A temperature in the range of 30–40 1C is suitable to obtain
good reproducibility [34]. It is better to push the drug peak further in
chromatogram as it results in separation of all degradation products.
Also a sufﬁcient run time after the drug peak is to be allowed to obtain
the degradants peak eluting after the drug peak [19].
During the method development it may happen that the drug peak
may hide an impurity or degradant peak that co-elutes with the drug.
This requires peak purity analysis which determines the speciﬁcity of
the method. Direct analysis can be done on line by using photo diode
array (PDA) detection. PDA provides information of the homogeneity
of the spectral peak but it is not applicable for the degradants that
have the similar UV spectrum to the drug. Indirect method involves
change in the chromatographic conditions like mobile phase ratio,
column, etc. which will affect the peak separation. The spectrum of
altered chromatographic condition is then compared with the original
spectra. If the degradant peaks and area percentage of the drug peak
remain same, then it can be conﬁrmed that the drug peak is
homogeneous [35]. The degradant that co-elutes with the drug would
be acceptable if it is not found to be formed in accelerated and long
term storage conditions [1]. The method is then optimized for
separating closely eluting peaks by changing ﬂow rate, injection
volume, column type and mobile phase ratio.
8.3. Method validation
The developed SIM is then validated according to USP/ICH
guideline for linearity, accuracy, precision, speciﬁcity, quantitation
limit, detection limit, ruggedness and robustness of the method.
It is required to isolate, identify and quantitate the degradants
found to be above identiﬁcation threshold (usually 0.1%) [36,37].
If the method does not fall within the acceptance criteria for
validation, the method is modiﬁed and revalidated [35].9. Other analytical methods for developing SIM
Stability-indicating methods will be characterized by potency,
purity and biological activity [38]. The selection of tests is productspeciﬁc. Stability indicating methods may include various methods
like electrophoresis (SDS-PAGE, immunoelectrophoresis, Western
blot, isoelectrofoccusing), high-resolution chromatography (e.g.,
reversed phase chromatography, SEC, gel ﬁltration, ion exchange,
and afﬁnity chromatography) and peptide mapping [39]. The
analytical method of choice should be sensitive enough to detect
impurities at low levels (i.e., 0.05% of the analyte of interest or
lower) and the peak responses should fall within the range of
detector's linearity. The analytical method should be capable of
capturing all the impurities formed during a formal stability study
at or below ICH threshold limits [40,41]. Degradation product
identiﬁcation and characterization are to be performed based on
formal stability results in accordance with ICH requirements.
Conventional methods (e.g., column chromatography) or hyphe-
nated techniques (e.g., LC–MS, LC–nuclear magnetic resonance
(NMR)) can be used in the identiﬁcation and characterization of
the degradation products. Use of these techniques can provide a
better insight into the structure of the impurities that could add to
the knowledge space of potential structural alerts for genotoxicity
and the control of such impurities with tighter limits [36,39–43]. It
should be noted that structural characterization of degradation
products is necessary for those impurities formed during formal
shelf-life stability studies and above the qualiﬁcation threshold
limit [40].
New analytical technologies that are continuously being devel-
oped can also be used when it is appropriate to develop stability
indicating method [44]. The unknown impurity, which is observed
during the analysis, pharmaceutical development, stress studies
and formal stability studies of the drug substances and drug
product, can be separated and analyzed by using various chroma-
tographic techniques like reversed phase high performance liquid
chromatography (RP-HPLC), thin layer chromatography (TLC),
gas chromatography (GC), capillary electrophoresis (CE), capillary
electrophoresis chromatography (CEC) and super critical ﬂuid
chromatography (SFC). An excellent combination of hyphenated
chromatographic and spectroscopic technique such as HPLC-
photodiode array ultraviolet detector (DAD), LC–MS, LC–NMR
and GC–MS are used when degradants cannot be isolated in pure
form. HPLC-DAD and LC–MS are used to compare the relative
retention time (RRT), UV spectra, mass spectra (MS/MS or MSN)
[29]. Singh and Rehman [45] discussed the role of hyphenated
systems for the isolation of degradants and impurities.10. Conclusion
Forced degradation studies provide knowledge about possible
degradation pathways and degradation products of the active
ingredients and help elucidate the structure of the degradants.
Degradation products generated from forced degradation studies
are potential degradation products that may or may not be formed
under relevant storage conditions but they assist in the developing
stability indicating method. It is better to start degradation studies
earlier in the drug development process to have sufﬁcient time to
gain more information about the stability of the molecule. This
information will in turn help improve the formulation manufactur-
ing process and determine the storage conditions. As no speciﬁc
set of conditions is applicable to all drug products and drug
substances and the regulatory guidance does not specify about the
conditions to be used, this study requires the experimenter to use
common sense. The aim of any strategy used for forced degrada-
tion is to produce the desired amount of degradation i.e., 5–20%.
Blessy M et al.164A properly designed and executed forced degradation study would
generate an appropriate sample for development of stability
indicating method.References
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